Authors
Latest:
Dr Plichta on Areas of Interest for Genetic Testing Research in Breast CancerJennifer K. Plichta, MD, MS, discusses key areas of interest regarding the role and optimization of genetic testing in breast cancer.
Latest:
Dr Myall on Immunotherapy Doublets and Chemoimmunotherapy in NSCLCNathaniel Myall, MD, clinical assistant professor, medicine - oncology, Stanford Medicine, discusses efficacy findings from 3 clinical trials investigating combination immunotherapy and chemoimmunotherapy treatment approaches in patients with non–small cell lung cancer.
Latest:
Advice for Community Oncologists Treating Patients With R/R MMDrs Lipe and Forsberg share advice for community oncologists and highlight unmet needs in the management of multiple myeloma.
Latest:
Evolving Treatment Landscape of MyelofibrosisClosing out their discussion on myelofibrosis management, experts from the John Theurer Cancer Center consider novel therapies under investigation and the future treatment paradigm.
Latest:
Dr. Rosenberg on Adapting Treatment Decisions Based on MRD in Multiple MyelomaAaron Seth Rosenberg, MD, MS, discusses the emerging role of minimal residual disease to guide treatment decisions in multiple myeloma.
Latest:
Dr. Galligan on Unmet Needs in High-Risk Multiple MyelomaDerek C. Galligan, MD, discusses unmet needs in high-risk multiple myeloma.
Latest:
Dr. Greenlee on Mitigating the Risk of Cardiovascular Disease in Breast CancerHeather Greenlee, ND, PhD, MPH, provides strategies to mitigate the increased risk of cardiovascular disease in women with breast cancer.
Latest:
Dr Montesinos on Quizartinib Plus Chemotherapy in Newly Diagnosed FLT3-ITD Wild-Type AMLPau Montesinos, MD, PhD, discusses preliminary efficacy seen with the addition of quizartinib to standard 7+3 chemotherapy in patients with newly diagnosed FLT3-ITD wild-type acute myeloid leukemia.
Latest:
Mentoring Oncologists in the Era of Social DistancingMentoring is critically important to the development of young academic hematology/oncology trainees.
Latest:
FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal CancerArvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results.
Latest:
Dr. von Mehren on Outcomes With Ribociclib/Everolimus in Dedifferentiated LiposarcomaMargaret von Mehren, MD, discusses outcomes with ribociclib and everolimus in dedifferentiated liposarcoma, as seen in the phase 2 SAR-096 trial.
Latest:
Dr. Abutalib on Recent Updates in CLLSyed A. Abutalib, MD, associate medical director, Hematologic Malignancies and Stem Cell Transplant Program, Cancer Treatment Centers of America, discusses recent updates in chronic lymphocytic leukemia.
Latest:
Dr Burgoyne on OS Data With Camrelizumab/Rivoceranib in Unresectable HCCAdam M. Burgoyne, MD, PhD, discusses updated findings from the CARES-310 trial and future considerations for unresectable HCC management.
Latest:
Dr. Moutafi on the Results of a Study Evaluating Biomarkers of Resistance in NSCLCMyrto Moutafi, MD, MSc, discusses the results of a study evaluating biomarkers of resistance in non–small cell lung cancer.
Latest:
Dr. Lazar on the Current State of Diagnosis and Treatment in Desmoid TumorsAlexander J. Lazar, MD, PhD, discusses the current state of diagnosis and treatment in desmoid tumors.
Latest:
Board Review Resources 2024Drs Armstrong and Tawagi discuss the board review plans they followed in the months leading up to their hematology and oncology board exams.
Latest:
Dr. Romancik on Maximizing CAR T-cell Therapy in NHLJason Romancik, MD, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma.
Latest:
Dr. Blanter on Racial Disparities in Development of Distant Metastases in Breast CancerJulia Blanter, MD, discusses the risk of developing distant metastases after initial breast cancer diagnosis among Black vs White women.
Latest:
Dr Gangat on JAK Inhibitor Selection in Treatment-Naive MyelofibrosisNaseema Gangat, MBBS discusses the clinical utility of momelotinib and JAK inhibitor selection in treatment-naive myelofibrosis.
Latest:
Dr Tiwari on the Current Treatment Paradigms for HER2-Positive and HER2-Low Breast CancersShruti Tiwari, MD, discusses how the treatment paradigms for HER2-positive and HER2-low breast cancer has evolved in recent years.
Latest:
Biomarkers Drive ICIs in Colon CancerDecember 14, 2020 - Immunotherapy agents have shown efficacy in malignant melanoma, kidney cancer, and non–small cell lung cancer, and investigators are examining the efficacy of checkpoint inhibitors in less immunogenic tumors such as colon cancer, particularly in tumors with high microsatellite instability and deficient mismatch repair genes.
Latest:
Siteman Cancer Center Names New Deputy Director Among Other Leadership AppointmentsSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis announces several leadership changes, including a new Deputy Director, Associate Directors of Translational Research and Shared Resources, and a Deputy Associate Director of Shared Resources.
Latest:
Dr DePalo on First-Line Therapies in Unresectable Melanoma In-Transit MetastasesDanielle K. DePalo, MD, discusses findings from a study comparing first-line isolated limb infusion/perfusion vs immune checkpoint inhibitors and intratumoral therapy in patients with surgically unresectable melanoma in-transit metastases.
Latest:
Dr. Maron on the Role of PD-1 Inhibition in Esophagogastric CancerSteven Maron, MD, MSc, discusses the role of PD-1 inhibition in esophagogastric cancer.
Latest:
Dr. Haakensen on Exclusion Criteria of a Named Patient Use Program in NSCLCVilde D. Haakensen, MD, PhD, discusses exclusion criteria for the Oslo University Hospital Named Patient Use program for adjuvant durvalumab in non–small cell lung cancer.
Latest:
Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCCPembrolizumab and platinum-based therapy elicited safe and efficacious outcomes in penile squamous cell carcinoma.
Latest:
UCLA Study Finds Combination Therapy Suppresses Pancreatic Tumor Growth in MiceUCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential new way to target pancreatic tumors that express high intratumoral interferon signaling
